explore -WSS

explore

author：fashion 2025-08-20 09:41:34 - browse：491

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Pioneering cancer drug will cost $475,000. Analysts call it a bargain

WSS

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

Mega Millions pot grows to $1.25 billion after no winner

Sage hopes for a blockbuster in antidepressant now before FDA

Sage hopes for a blockbuster in antidepressant now before FDA

Bispecific antibodies are next new thing in cancer immunotherapy

Physician groups backed by private equity giant lobby on mergers

focus

explore

entertainment

Apple is now the first public company to be valued at $3 trillion

Lawsuit alleges UnitedHealth Group unit illegally denied claims

Heart attack and stroke risk calculators need revising

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

BioMarin wins approval for gene therapy to treat hemophilia A

How to fix the rural physician shortage in the U.S.

Hollywood unions extend contract negotiations for actors

Mitch McConnell episode has important public health takeaway

23andMe had bad news about my health. I wish a person had delivered it

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

explore

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

NIH launches clinical trials and new research office for long Covid

New safety details link Apellis eye drug to rare cases of blindness

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

Mega Millions pot grows to $1.25 billion after no winner

explore

focus

focus

hotspot